Viva Biotech Holdings
Viva Biotech Holdings, a leading player in the biotechnology sector, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2008, the company has established itself as a prominent provider of drug discovery services, specialising in structure-based drug design and high-throughput screening. Viva Biotech's unique offerings include its proprietary technology platforms that enhance the efficiency of drug development processes, setting it apart in a competitive market. With a strong focus on innovation, the company has achieved significant milestones, including collaborations with major pharmaceutical firms and a robust portfolio of successful projects. Recognised for its expertise and commitment to advancing biopharmaceutical research, Viva Biotech Holdings continues to solidify its position as a trusted partner in the global biotech landscape.
DitchCarbon Score
How does Viva Biotech Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viva Biotech Holdings's score of 5 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Viva Biotech Holdings's reported carbon emissions
In 2023, Viva Biotech Holdings reported total carbon emissions of approximately 46,731,280 kg CO2e, comprising 1,466,050 kg CO2e from Scope 1 and 45,285,230 kg CO2e from Scope 2 emissions. This marked a slight decrease from the previous year's total emissions of about 46,779,490 kg CO2e. In 2022, the company’s emissions included 1,404,350 kg CO2e from Scope 1 and 45,376,870 kg CO2e from Scope 2. Over the years, emissions have fluctuated, with 2021 showing a total of approximately 37,456,150 kg CO2e, which included 958,110 kg CO2e from Scope 1 and 36,499,030 kg CO2e from Scope 2. Despite these figures, Viva Biotech has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or SBTi (Science Based Targets initiative) commitments suggests that the company may still be in the early stages of formalising its climate strategy. Overall, while the company has made some progress in managing its emissions, further transparency regarding its climate commitments and reduction strategies would be beneficial for stakeholders and the environment.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 152,010 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 27,929,350 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viva Biotech Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
